Search

Your search keyword '"Gaitani, S"' showing total 41 results
Start Over Author "Gaitani, S"
41 results on '"Gaitani, S"'

2. Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia

Author

PICCALUGA, PIER PAOLO, MALAGOLA, MICHELE, RONDONI, MICHELA, AMABILE, MARILINA, PAOLINI, STEFANIA, SOVERINI, SIMONA, BACCARANI, MICHELE, MARTINELLI, GIOVANNI, GAITANI S, VISANI G, PICCALUGA PP, MALAGOLA M, RONDONI M, AMABILE M, PAOLINI S, SOVERINI S, GAITANI S, VISANI G, BACCARANI M., and MARTINELLI G

Subjects
BCR/ABL-POSITIVE ACUTE LYMPHOID LEUKAEMIA, IMATINIB
Abstract

NA

Published
2004

3. Instillazione diretta intranasale di amfotericina B liposomiale nella terapia delle micosi nasali

Author

PICCALUGA, PIER PAOLO, RONDONI, MICHELA, MARTINELLI, GIOVANNI, Ricci P, Malagola M, Vigna E, Bosi C, Gaitani S, Visani G, Piccaluga PP, Ricci P, Malagola M, Rondoni M, Vigna E, Bosi C, Gaitani S, Visani G, and Martinelli G.

Subjects
ambisome, intra-nasal administration, ACUTE MYELOID LEUKAEMIA
Abstract

Le infezioni fungine viscerali sono una severa complicanza durante la chemioterapia nei pazienti con leucemia acuta mieloide (LAM) (1). In particolare, le Aspergillus spp. e le Candida species sono spesso responsabili di gravi infezioni in questo tipo di pazienti, durante le fasi di agranulocitosi. Il polmone ed i seni nasali sono le sedi più frequentemente interessate da questi patogeni. Entrambi questi tipi di infezione possono essere letali, essendo possibili eventi terminali drammatici l’interessamento dei vasi bronchiali principali (con conseguente emottisi massiva) e l’infiltrazione del sistema nervoso centrale attraverso la lamina cribrosa dell’osso etmoide. Anche l’interessamento epato-splenico è un evento non raro. Il recupero granulocitario ed un tempestivo trattamento specifico per via sistemica sono necessari per controllare l’infezione.Al momento, l’amfotericina-B deossicolato per e.v. è il farmaco più comunemente impiegato per il trattamento di queste forme; peraltro, la nefrotossicità e le reazioni infusionali sono effetti indesiderati molto comuni (2). La formulazione liposomiale dell’amfotericina- B (AmBisome) (GILEAD SCIENCE) si è rivelata particolarmente efficace e con un favorevole profilo di tossicità e viene pertanto comunemente utilizzata per i pazienti che risultino intolleranti alla formulazione convenzionale (3). Questi due farmaci possono essere impiegati anche in forma di aerosol, al fine di aumentare la concentrazione a livello polmonare riducendo la tossicità sistemica (4, 5). Inoltre, sono stati riportati successi con l’instillazione diretta di agenti antifungini in aspergillomi polmonari (6). In casi selezionati, per aspergillomi isolati,può essere proposta una terapia chirurgica.Infine, in caso di micosi invasiva, possono essere utilizzate anche trasfusioni di granulociti (7).Alcuni nuovi farmaci, sviluppati recentemente, hanno mostrato risultati promettenti, ma, allo stato attuale, non sono ancora comunemente adottati. Noi abbiamo utilizzato con successo AmBisome, e. v. e per la prima volta anche per diretta instillazione intranasale, in due pazienti con LAM e micosi dei seni nasali. In un caso, è stata anche associata la trasfusione di granulociti.

Published
2004

4. Imatinib mesylate in the treatment of c-kit–positive acute myeloid leukemia: is this the real target?

Author

Malagola, M., Martinelli, G., Rondoni, M., Paolini, S., Gaitani, S., Arpinati, M., Piccaluga, P. P., Amabile, M., Basi, C., Ottaviani, E., Candoni, A., Gottardi, E., Cilloni, D., Bocchia, M., Saglio, G., Lauria, F., Fanin, R., Visani, G., Marrè, M. C., Maderna, M., Rancati, F., Vinaccia, V., Russo, D., Baccarani, M., Kindler, T., Heidel, F., Fischer, T., Malagola M, Martinelli G, Rondoni M, Paolini S, Gaitani S, Arpinati M, Piccaluga PP, Amabile M, Basi C, Ottaviani E, Candoni A, Gottardi E, Cilloni D, Bocchia M, Saglio G, Lauria F, Fanin R, Visani G, Marre MC, Maderna M, Rancati F, Vinaccia V, Russo D, and Baccarani M.

Subjects
Oncology, medicine.medical_specialty, business.industry, Immunology, IMATINIB MESYLATE, Myeloid leukemia, Imatinib, Cell Biology, Hematology, medicine.disease, Biochemistry, C-KIT, Leukemia, Imatinib mesylate, hemic and lymphatic diseases, Internal medicine, medicine, Conventional chemotherapy, ACUTE MYELOID LEUKEMIA, business, neoplasms, medicine.drug
Abstract

Kindler et al[1][1] reported that 5 of 21 acute myeloid leukemia (AML) patients responded to treatment with imatinib mesylate, which is a c-kit inhibitor. From February 2003 to November 2003, we treated with imatinib 36 c-kit–positive AML patients who were not amenable to conventional chemotherapy

Published
2005
Full Text
View/download PDF

8. Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: Is this the real target? [3] (multiple letters)

Author

Malagola, M., Martinelli, G., Rondoni, M., Paolini, S., Gaitani, S., Arpinati, M., Piccaluga, P. P., Amabile, M., Basi, C., Ottaviani, E., Candoni, A., Gottardi, E., Cilloni, D., Bocchia, M., Saglio, G., Lauria, F., Fanin, R., Visani, G., Marre, M. C., Maderna, M., Rancati, F., Vinaccia, V., Russo, D., Baccarani, M., Kindler, T., Heidel, F., and Fischer, T.

Published
2005

9. Idiopathic hypereosinphilic synndrome (HES) with FIP1L1-PDGFR-alpha rearrangement can be effectively treated with imatinib

Author

Martinelli, G, Cilloni, D, Ottaviani, E, Malagola, Michele, Messa, F, Rondoni, M, Bosi, C, Gottardi, E, Rosti, G, Ricci, P, Gaitani, S, Pane, F, Testoni, N, Mecucci, C, Soverini, S, Piccaluga, Pp, Amabile, M, Tiribelli, M, Zaccaria, A, Grafone, T, De Vivo, A, Pileri, S, Fattori, Pp, Bocchia, M, Serra, A, Maurillo, L, Fanin, R, Cross, N, Merante, S, Cazzola, M, Alimena, G, Frassoni, F, Galieni, P, Russo, Domenico, Gobbi, M, Gugliotta, L, Lauria, F, Mazza, P, Ferrara, F, Gherlinzoni, F, Leoni, P, Pellegrino, M, Baccarani, M, and Saglio, G.

Published
2004

16. Italian Cooperative study on idiopathic hypereosinophilic syndrome (HES): FIP1-L1/PDGFRA rearrangement can be effectively treated with Imatinib

Author

Martinelli, G, Cilloni, D, Ottavini, E, Malagola, Michele, Cross, N, Rosti, G, Gaitani, S, Pane, F, Giannini, B, Testoni, N, Mecucci, C, Soverini, S, Piccaluga, Pp, Rondoni, M, Amabile, M, Tiribelli, M, Bosi, C, Poerio, A, Zuffa, E, Zaccaria, A, Grafone, T, De Vivo, A, Ascani, S, Pileri, S, Visani, G, Fattori, P, Bocchia, M, Serra, A, Gottardi, E, Maurillo, L, Merante, S, Cazzola, M, Fanin, R, Saglio, G, Bertieri, R, and Baccarani, M.

Published
2003

20. Poster session V * Saturday 11 December 2010, 08:30-12:30

Author

Pham, Q. H., primary, Von Lueder, T. G., additional, Namtvedt, S. K., additional, Rosjo, H., additional, Omland, T., additional, Steine, K., additional, Timoteo, A. T., additional, Mota Carmo, M., additional, Simoes, M., additional, Branco, L. M., additional, Ferreira, R. C., additional, Kato, R., additional, Ito, J., additional, Tahara, T., additional, Yokoyama, Y., additional, Ashikaga, T., additional, Satoh, Y., additional, Na, J. O., additional, Hong, H. E., additional, Kim, M. N., additional, Shin, S. Y., additional, Choi, C. U., additional, Kim, E. J., additional, Rha, S. W., additional, Park, C. G., additional, Seo, H. S., additional, Oh, D. J., additional, Ticulescu, R., additional, Brigido, S., additional, Vriz, O., additional, Sparacino, L., additional, Popescu, B. A., additional, Ginghina, C., additional, Carerj, S., additional, Nicolosi, G. L., additional, Antonini-Canterin, F., additional, Onaindia Gandarias, J. J., additional, Romero, A., additional, Laraudogoitia, E., additional, Velasco, S., additional, Quintana, O., additional, Cacicedo, A., additional, Rodriguez, I., additional, Alarcon, J. A., additional, Gonzalez, J., additional, Lekuona, I., additional, Subinas, A., additional, Abdula, G., additional, Lund, L. H., additional, Winter, R., additional, Brodin, L., additional, Sahlen, A., additional, Masaki, M., additional, Cha, Y. M., additional, Yuasa, T., additional, Dong, K., additional, Dong, Y. X., additional, Mankad, S. V., additional, Oh, J. K., additional, Vallet, F., additional, Lequeux, B., additional, Diakov, C., additional, Sosner, P., additional, Christiaens, L., additional, Coisne, D., additional, Kihara, C., additional, Murata, K., additional, Wada, Y., additional, Uchida, K., additional, Ueyama, T., additional, Okuda, S., additional, Susa, T., additional, Matsuzaki, M., additional, Cho, E. J., additional, Choi, K. Y., additional, Kwon, B. J., additional, Kim, D. B., additional, Jang, S. W., additional, Cho, J. S., additional, Jung, H. O., additional, Jeon, H. K., additional, Youn, H. J., additional, Kim, J. H., additional, Cikes, M., additional, Bijnens, B., additional, Velagic, V., additional, Kopjar, T., additional, Milicic, D., additional, Biocina, B., additional, Gasparovic, H., additional, Almuntaser, I., additional, Brown, A., additional, Foley, B., additional, Mulvihill, N., additional, Crean, P., additional, King, G., additional, Murphy, R., additional, Takata, Y., additional, Taniguchi, M., additional, Nobusada, S., additional, Sugawara, M., additional, Toh, N., additional, Kusano, K., additional, Itoh, H., additional, Wellnhofer, E., additional, Kriatselis, C., additional, Nedios, S., additional, Gerds-Li, J. H., additional, Fleck, E., additional, Poulsen, M. K., additional, Henriksen, J. E., additional, Dahl, J., additional, Johansen, A., additional, Haghfelt, T., additional, Hoilund-Carlsen, P. F., additional, Beck-Nielsen, H., additional, Moller, J. E., additional, Dankowski, R., additional, Wierzchowiecki, M., additional, Michalski, M., additional, Nowicka, A., additional, Szymanowska, K., additional, Pajak, A., additional, Poprawski, K., additional, Szyszka, A., additional, Kasner, M., additional, Westermann, D., additional, Schultheiss, H. P., additional, Tschoepe, C., additional, Watanabe, T., additional, Iwai-Takano, M., additional, Kobayashi, A., additional, Machii, H., additional, Takeishi, Y., additional, Paelinck, B. P., additional, Van Herck, P. L., additional, Bosmans, J. M., additional, Vrints, C. J., additional, Lamb, H. J., additional, Doltra, A., additional, Vidal, B., additional, Silva, E., additional, Poyatos, S., additional, Mont, L., additional, Berruezo, A., additional, Castel, A., additional, Tolosana, J. M., additional, Brugada, J., additional, Sitges, M., additional, Dencker, M., additional, Bjorgell, O., additional, Hlebowicz, J., additional, Szelenyi, Z. S., additional, Szenasi, G., additional, Kiss, M., additional, Prohaszka, Z., additional, Patocs, A., additional, Karadi, I., additional, Vereckei, A., additional, Saha, S. K., additional, Anderson, P. L., additional, Govind, S., additional, Govindan, M., additional, Moggridge, J. C., additional, Kiotsekoglou, A., additional, Gopal, A. S., additional, Loegstrup, B. B., additional, Christophersen, T. B., additional, Hoefsten, D. E., additional, Moeller, J. E., additional, Boetker, H. E., additional, Egstrup, K., additional, Graefe, M., additional, Huang, F. Q., additional, Zhang, R. S., additional, Le, T. T., additional, Tan, R. S., additional, Sattarzadeh Badkoubeh, R., additional, Tavoosi, A., additional, Elahian, A. R., additional, Drapkina, O., additional, Ivashkin, V. I., additional, Fazakas, A., additional, Pepo, L., additional, Janosi, O., additional, Kopitovic, I., additional, Goncalves, A., additional, Marcos-Alberca, P., additional, Almeria, C., additional, Feltes, G., additional, Rodriguez, E., additional, Garcia, E., additional, Hernandez-Antolin, R., additional, Macaya, C., additional, Silva Cardoso, J., additional, Zamorano, J. L., additional, Navarro, M. S., additional, Valentin, M., additional, Banes, C. M., additional, Rigo, F., additional, Grolla, E., additional, Tona, F., additional, Cuaia, V., additional, Moreo, A., additional, Badano, L., additional, Raviele, A., additional, Iliceto, S., additional, Tarzia, P., additional, Sestito, A., additional, Nerla, R., additional, Di Monaco, A., additional, Infusino, F., additional, Matera, D., additional, Greco, F., additional, Tacchino, R. M., additional, Lanza, G. A., additional, Crea, F., additional, Nemes, A., additional, Balazs, E., additional, Pinter, K. S., additional, Egyed, A., additional, Csanady, M., additional, Forster, T., additional, Holte, E., additional, Vegsundvag, J., additional, Hole, T., additional, Hegbom, K., additional, Wiseth, R., additional, Sharif, D., additional, Sharif-Rasslan, A., additional, Shahla, C., additional, Khalil, A., additional, Rosenschein, U., additional, Zagatina, A., additional, Zhuravskaya, N., additional, Tyurina, T. V., additional, Tagliamonte, E., additional, Cirillo, T., additional, Coppola, A., additional, Marinelli, U., additional, Romano, C., additional, Riccio, G., additional, Citro, R., additional, Astarita, C., additional, Capuano, N., additional, Quaranta, G., additional, Desiderio, A., additional, Frattini, S., additional, Faggiano, P., additional, Zilioli, V., additional, Locantore, E., additional, Longhi, S., additional, Bellandi, F., additional, Faden, G., additional, Triggiani, M., additional, Dei Cas, L., additional, Dalsgaard, M., additional, Kjaergaard, J., additional, Iversen, K., additional, Hassager, C., additional, Dinh, W., additional, Nickl, W. N., additional, Smettan, J. S., additional, Koehler, T. K., additional, Scheffold, T. D., additional, Coll Barroso, M. C. B., additional, Guelker, J. G., additional, Fueth, R. F., additional, Kamperidis, V., additional, Hadjimiltiades, S., additional, Sianos, G., additional, Efthimiadis, G., additional, Karvounis, H., additional, Parcharidis, G., additional, Styliadis, I. H., additional, Velasco Del Castillo, M. S., additional, Onaindia, J. J., additional, Telleria, M., additional, Carstensen, H. G., additional, Nordenberg, C., additional, Sogaard, P., additional, Fritz-Hansen, T., additional, Bech, J., additional, Galatius, S., additional, Jensen, J. S., additional, Mogelvang, R., additional, Bartko, P. E., additional, Graf, S., additional, Rosenhek, R., additional, Burwash, I. G., additional, Bergler-Klein, J., additional, Clavel, M.-A., additional, Baumgartner, H., additional, Pibarot, P., additional, Mundigler, G., additional, Kirilmaz, B., additional, Eser, I., additional, Tuzun, N., additional, Komur, B., additional, Dogan, H., additional, Taskiran Comez, A., additional, Ercan, E., additional, Cusma-Piccione, M., additional, Zito, C., additional, Oreto, G., additional, Piluso, S., additional, Tripepi, S., additional, Oreto, L., additional, Longordo, C., additional, Ciraci, L., additional, Di Bella, G., additional, Piatkowski, R., additional, Kochanowski, J., additional, Scislo, P., additional, Grabowski, M., additional, Marchel, M., additional, Roik, M., additional, Kosior, D., additional, Opolski, G., additional, Sknouril, L., additional, Dorda, M., additional, Holek, B., additional, Gajdusek, L., additional, Chovancik, J., additional, Branny, M., additional, Fiala, M., additional, Szymanski, P., additional, Lipczynska, M., additional, Klisiewicz, A., additional, Hoffman, P., additional, Jander, N., additional, Minners, J., additional, Martin, G., additional, Zeh, W., additional, Allgeier, M., additional, Gohlke-Baewolf, C., additional, Gohlke, H., additional, Nistri, S., additional, Porciani, M. C., additional, Attanasio, M., additional, Abbate, R., additional, Gensini, G. F., additional, Pepe, G., additional, Duncan, R. F., additional, Piantadosi, C., additional, Nelson, A. J., additional, Wittert, G., additional, Dundon, B., additional, Worthley, M. I., additional, Worthley, S. G., additional, Jung, P., additional, Berlinger, K., additional, Rieber, J., additional, Sohn, H. Z., additional, Schneider, P., additional, Leibig, M., additional, Koenig, A., additional, Klauss, V., additional, Tomkiewicz-Pajak, L., additional, Kolcz, J., additional, Olszowska, M., additional, Pieculewicz, M., additional, Podolec, P., additional, Przewlocki, T., additional, Suchon, E., additional, Sobien, B., additional, Wilkolek, P., additional, Ziembicka, A., additional, Hlawaty, M., additional, Van De Bruaene, A., additional, Hermans, H., additional, Buys, R., additional, Vanhees, L., additional, Delcroix, M., additional, Voigt, J.-U., additional, Budts, W., additional, De Cillis, E., additional, Acquaviva, T., additional, Basile, D., additional, Bortone, A. S., additional, Kalimanovska-Ostric, D., additional, Nastasovic, T., additional, Vujisic-Tesic, B., additional, Jovanovic, I., additional, Milakovic, B., additional, Dostanic, M., additional, Stosic, M., additional, Frogoudaki, A., additional, Andreou, K., additional, Parisis, J., additional, Triantafyllidi, E., additional, Gaitani, S., additional, Paraskevaidis, J., additional, Anastasiou-Nana, M., additional, De Pasquale, G., additional, Kuehn, A., additional, Petzuch, K., additional, Mueller, J., additional, Meierhofer, C., additional, Fratz, S., additional, Hager, A., additional, Hess, J., additional, Vogt, M., additional, Attenhofer Jost, C. H., additional, Dearani, J. A., additional, Scott, C. G., additional, Burkhart, H. M., additional, Connolly, H. M., additional, Vitarelli, A., additional, Battaglia, D., additional, Caranci, F., additional, Padella, V., additional, Continanza, G., additional, Dettori, O., additional, Capotosto, L., additional, Vitarelli, M., additional, De Cicco, V., additional, Cortez Morichetti, M., additional, Mohanan Nair, K. K., additional, Sasidaharan, B., additional, Thajudeen, A., additional, Tharakan, J. M., additional, Mertens, L., additional, Ahmad, N., additional, Kantor, P. K., additional, Grosse-Wortmann, L., additional, Friedberg, M. K., additional, Bernard, Y. F., additional, Morel, M. A., additional, Descotes-Genon, V., additional, Jehl, J., additional, Meneveau, N., additional, Schiele, F., additional, Kaldararova, M., additional, Simkova, I., additional, Tittel, P., additional, Masura, J., additional, Trojnarska, O., additional, Szczepaniak, L., additional, Mizia -Stec, K., additional, Cieplucha, A., additional, Bartczak, A., additional, Grajek, S., additional, Tykarski, A., additional, Gasior, Z., additional, Babovicvuksanovic, D., additional, Bonnichsen, C. R., additional, Morgan, G. J., additional, Slorach, C., additional, Hui, W., additional, Sarkola, T., additional, Lee, K. J., additional, Chaturvedi, R., additional, Benson, L., additional, Bradley, T., additional, Iancu, M. E., additional, Ghiorghiu, I., additional, Serban, M., additional, Craciunescu, I., additional, Hodo, A., additional, Morgan, J., additional, Roche, L., additional, Lee, K., additional, Milanesi, O., additional, Favero, V., additional, Padalino, M., additional, Biffanti, R., additional, Cerutti, A., additional, Maschietto, N., additional, Reffo, E., additional, Vida, V., additional, Stellin, G., additional, Irtyuga, O., additional, Gamazin, D., additional, Voronkina, I., additional, Tsoyi, N., additional, Gudkova, E., additional, Moiseeva, O., additional, Aggeli, C., additional, Kazazaki, C., additional, Felekos, I., additional, Lagoudakou, S., additional, Roussakis, G., additional, Skoumas, J., additional, Pitsavos, C., additional, Stefanadis, C., additional, Cueff, C., additional, Keenan, N., additional, Steg, P. G., additional, Cimadevilla, C., additional, Ducrocq, G., additional, Vahanian, A., additional, Messika-Zeitoun, D., additional, Petrella, L., additional, Mazzola, A. M., additional, Villani, C. V., additional, Giancola, R. G., additional, Ciocca, M. C., additional, Di Eusanio, D. E. M., additional, Nolan, S., additional, Ionescu, A., additional, Skaug, T. R., additional, Amundsen, B. H., additional, Hergum, T., additional, Torp, H., additional, Haugen, B. O., additional, Lopez Aguilera, J., additional, Mesa Rubio, D., additional, Ruiz Ortiz, M., additional, Delgado Ortega, M., additional, Villanueva Fernandez, E., additional, Cejudo Diaz Del Campo, L., additional, Toledano Delgado, F., additional, Leon Del Pino, M., additional, Romo Pena, E., additional, Suarez De Lezo Cruz-Conde, J., additional, De Marco, E., additional, Colucci, A., additional, Comerci, G., additional, Gabrielli, F. A., additional, Natali, R., additional, Garramone, B., additional, Savino, M., additional, Lotrionte, M., additional, Sonaglioni, A., additional, Loperfido, F., additional, Zdravkovic, M., additional, Perunicic, J., additional, Krotin, M., additional, Ristic, M., additional, Vukomanovic, V., additional, Zaja, M., additional, Radovanovic, S., additional, Saric, J., additional, Zdravkovic, D., additional, Cotrim, C., additional, Almeida, A. R., additional, Miranda, R., additional, Almeida, A. G., additional, Picano, E., additional, Carrageta, M., additional, D'andrea, A., additional, Cocchia, R., additional, Riegler, L., additional, Golia, E., additional, Scarafile, R., additional, Caso, P., additional, Russo, M. G., additional, Bossone, E., additional, Calabro', R., additional, Noman, H., additional, Adel, A., additional, Elfaramawy, A. M. R., additional, Abdelraouf, M., additional, Elnaggar, W. A. E. L., additional, Baligh, E., additional, Sargento, L., additional, Silva, D., additional, Goncalves, S., additional, Ribeiro, S., additional, Vinhas Sousa, G., additional, Almeida, A., additional, Lopes, M., additional, Rodriguez-Manero, M., additional, Aguado Gil, L., additional, Azcarate, P., additional, Lloret Luna, P., additional, Macias Gallego, A., additional, Castano, S. A. R. A., additional, Garcia, M., additional, Pujol Salvador, C., additional, Barba, J., additional, Redondo, P., additional, Tomasoni, L., additional, Sitia, S., additional, Atzeni, F., additional, Gianturco, L., additional, Ricci, C., additional, Sarzi-Puttini, P., additional, Turiel, M., additional, De Gennaro Colonna, V., additional, Uejima, T., additional, Jaroch, J., additional, Polombo, C., additional, Hughes, A., additional, Vinereanu, D., additional, Evanvelista, A., additional, Leftheriotis, G., additional, Fraser, A. G., additional, Lewczuk, A., additional, Sobkowicz, B., additional, Tomaszuk-Kazberuk, A., additional, Sawicki, R., additional, Hirnle, T., additional, Michalski, B. W., additional, Filipiak, D., additional, Kasprzak, J. D., additional, Lipiec, P., additional, Dalen, H., additional, Mjolstad, O. C., additional, Klykken, B. E., additional, Graven, T., additional, Martensson, M., additional, Olsson, M., additional, Brodin, L.-A., additional, Enache, R., additional, Leiballi, E., additional, Penhall, A., additional, Perry, R., additional, Altman, M., additional, Sinhal, A., additional, Bennetts, J., additional, Chew, D. P., additional, Joseph, M. X., additional, Larsen, L. H., additional, Kristensen, T., additional, Kober, L. V., additional, Kofoed, K. F., additional, Moscoso Costa, F., additional, Ribeiras, R., additional, Brito, J., additional, Boshoff, S., additional, Neves, J., additional, Teles, R., additional, Canada, M., additional, Andrade, M. J., additional, Gouveia, R., additional, Silva, A., additional, Miskovic, A., additional, Poerner, T. P., additional, Stiller, C. S., additional, Goebel, B. G., additional, Moritz, A. M., additional, Stefani, L., additional, Galanti, G. G., additional, Moraldo, M., additional, Bergamini, C., additional, Pabari, P. A., additional, Dhutia, N. M., additional, Malaweera, A. S. N., additional, Willson, K., additional, Davies, J., additional, Hughes, A. D., additional, Xu, X. Y., additional, Francis, D. P., additional, Jasaityte, R., additional, Amundsen, B., additional, Barbosa, D., additional, Loeckx, D., additional, Kiss, G., additional, Orderud, F., additional, Robesyn, V., additional, Claus, P., additional, D'hooge, J., additional, Nao, T., additional, Miura, T., additional, Shams, K., additional, Samir, S., additional, Samir, R., additional, El-Sayed, M., additional, Anwar, A. M., additional, Nosir, Y., additional, Galal, A., additional, Chamsi-Pasha, H., additional, Ciobanu, A., additional, Dulgheru, R., additional, Bennett, S., additional, De Luca, A., additional, Toncelli, L., additional, Cappelli, F., additional, Cappelli, B., additional, Vono, M. C. R., additional, Galanti, G., additional, Zorman, Y., additional, Yilmazer, M. S., additional, Akyildiz, M., additional, Gurol, T., additional, Aydin, A., additional, Dagdeviren, B., additional, and Kalangos, A., additional

Published
2010
Full Text
View/download PDF

30. Gemtuzumab Ozogamicin for Relapsed and Refractory Acute Myeloid Leukemia and Myeloid Sarcomas

Author

Monica Morselli, Michele Malagola, Michele Baccarani, Mario Luppi, Giuseppe Visani, Giovanni Sparaventi, Alessandro Bonini, Luigi Gugliotta, Michela Rondoni, Pier Paolo Piccaluga, Stavroula Gaitani, Alessandro Isidori, Giovanni Martinelli, PICCALUGA PP, MARTINELLI G., RONDONI M, MALAGOLA M, GAITANI S, ISIDORI A, BONINI A, GUGLIOTTA L, LUPPI M, MORSELLI M, SPARAVENTI G, VISANI G, and BACCARANI M.

Subjects
Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, Myeloid, Gemtuzumab ozogamicin, antibody-targeted chemotherapy, acute myeloid leukemia, Neutropenia, Antibodies, Monoclonal, Humanized, chemistry.chemical_compound, Recurrence, Cause of Death, hemic and lymphatic diseases, Internal medicine, Calicheamicin, myeloid sarcoma, medicine, Myeloid sarcoma, gemtuzumab ozogamicin, Humans, Sarcoma, Myeloid, Aged, business.industry, Antibodies, Monoclonal, Myeloid leukemia, Hematology, Middle Aged, bleeding, medicine.disease, Gemtuzumab, Leukemia, Myeloid, Acute, Leukemia, Aminoglycosides, Treatment Outcome, medicine.anatomical_structure, chemistry, Immunology, Female, Immunotherapy, Sarcoma, business, medicine.drug
Abstract

Antibody-targeted chemotherapy is a promising approach in patients with hematological malignancies. In particular, gemtuzumab ozogamicin (GO, formerly CMA-676), an anti-CD33 antibody linked to calicheamicin, has been approved for the treatment of elderly patients with acute myeloid leukemia (AML) in relapse. Nevertheless, no data are until now available concerning the possible efficacy of GO for myeloid sarcomas (MS). We treated with GO 24 AML patients, in 5 cases presenting with myeloid sarcomas of the skin or bones. The overall complete response rate was 21%. The median duration of response was 6 months. Four out of the 5 patients with myeloid sarcoma showed a regression of the masses, in two cases also obtaining a clearance of marrow blasts. The most common adverse events included thrombocytopenia, neutropenia, infections, elevation of bilirubin and hepatic transaminases. Notably, severe bleeding occurred in 5 cases (21%). VOD was documented in 1 case. We conclude that GO is effective as a single agent in AML and myeloid sarcomas. Further data are required to clarify the possible correlation between GO administration and occurrence of bleeding.

Published
2004
Full Text
View/download PDF

31. Anti-Leukemic and Anti-GVHD Effects of Campath-1H in Acute Lymphoblastic Leukemia Relapsed after Stem-Cell Transplantation

Author

Ernesto Vigna, Michele Malagola, Giovanni Martinelli, Michele Bianchini, Stavroula Gaitani, Giuseppe Visani, Michele Baccarani, Pier Paolo Piccaluga, Costanza Bosi, Michela Rondoni, PICCALUGA PP, MARTINELLI G, MALAGOLA M, RONDONI M, BIANCHINI M, VIGNA E, BOSI C, GAITANI S, VISANI G, and BACCARANI M.

Subjects
Adult, Male, Cancer Research, Adolescent, Antibodies, Neoplasm, medicine.drug_class, medicine.medical_treatment, Graft vs Host Disease, Salvage therapy, Antineoplastic Agents, Hematopoietic stem cell transplantation, Antibodies, Monoclonal, Humanized, Monoclonal antibody, Donor lymphocyte infusion, Recurrence, medicine, Humans, Alemtuzumab, Salvage Therapy, business.industry, Hematopoietic Stem Cell Transplantation, Antibodies, Monoclonal, Hematology, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Transplantation, Treatment Outcome, surgical procedures, operative, medicine.anatomical_structure, Oncology, Immunology, Drug Evaluation, Female, Bone marrow, Stem cell, business, medicine.drug
Abstract

Despite aggressive approaches, including second transplant, donor lymphocyte infusion and several new agents, the prognosis of acute lymphoid leukemia (ALL) patients relapsing after stem-cell transplantation (SCT) remains poor. Monoclonal-antibodies (moAb) could provide a useful tool in this setting. In particular, anti-CD52 moAb is useful in lymphoid malignancies. We thus treated as compassionate with campath-1H 3 ALL patients relapsed after SCT. In 2 cases we observed a reduction of peripheral blood and/or bone marrow blasts. In 1 case a GVHD grade reduction was observed. Larger trials are required in order to define the role of campath-1H in ALL.

Published
2004
Full Text
View/download PDF

32. Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia

Author

Michele Baccarani, Michela Rondoni, Nicoletta Testoni, Pier Paolo Piccaluga, Stefano Pileri, Stavroula Gaitani, Stefano Ascani, Simona Luatti, Michele Malagola, Michele Bianchini, Giuseppe Visani, Giovanni Martinelli, PICCALUGA PP, LUATTI S, ASCANI S, BIANCHINI M, MALAGOLA M, RONDONI M, GAITANI S, TESTONI N., PILERI SA, BACCARANI M, MARTINELLI G, and VISANI G

Subjects
Cancer Research, ACUTE MYELOID-LEUKEMIA, Biology, Middle Aged, Translocation, Genetic, RESIDUAL DISEASE, ADULT, Immunophenotyping, Leukemia, Myeloid, Acute, Chromosomes, Human, Pair 1, Karyotyping, Genetics, Cancer research, Humans, Identification (biology), Myelocytic leukemia, Female, Chromosomes, Human, Pair 9, Molecular Biology
Published
2004

33. First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients

Author

Giovanni Martinelli, Pier Paolo Piccaluga, Michele Baccarani, Stavroula Gaitani, Michela Rondoni, Michele Malagola, Giuseppe Visani, PICCALUGA PP, MARTINELLI G, RONDONI M, MALAGOLA M, GAITANI S, VISANI G, and BACCARANI M.

Subjects
Cancer Research, medicine.medical_specialty, Gemtuzumab ozogamicin, Continuous infusion, Hemorrhage, Antibodies, Monoclonal, Humanized, Gastroenterology, chemistry.chemical_compound, AML, Recurrence, Internal medicine, Calicheamicin, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Prospective cohort study, Adverse effect, Aged, business.industry, Remission Induction, Cytarabine, Antibodies, Monoclonal, Hematology, Middle Aged, GEMTUZUMAB OZOGAMICIN, Gemtuzumab, Surgery, Survival Rate, Regimen, Aminoglycosides, Treatment Outcome, Oncology, chemistry, Leukemia, Myeloid, Acute Disease, Myeloid leukaemia, business, medicine.drug
Abstract

Gemtuzumab ozogamicin (GO), an anti-CD33 monoclonal antibody conjugated to calicheamicin, is effective as single agent in the treatment of poor risk acute myeloid leukaemia (AML) patients. We treated with GO in combination with cytarabine as continuous perfusion nine elderly AML patients, either untreated (five cases), or with relapsed/refractory disease (four cases). Five patients achieved a complete remission (CR), four were resistant. One patient died while in CR due to CNS haemorrhage, two relapsed and two are still in CR. The median CR duration was 10 months. The median overall survival was 6 months (1-19 months). The most common adverse event was myelosuppression, as expected. No hepatic veno-occlusive disease was recorded. Notably, in four cases we observed a grade III/IV bleeding, including gasto-intestinal bleeding, epistaxis, CNS haemorrhage, and ocular bleeding. Larger prospective studies are now warranted in order to better define the possible role of this regimen in the treatment of elderly AML patients.

Published
2003

34. Plasma B-type natriuretic peptide and anti-inflammatory cytokine interleukin-10 levels predict adverse clinical outcome in chronic heart failure patients with depressive symptoms: a 1-year follow-up study.

Author

Parissis JT, Farmakis D, Nikolaou M, Birmpa D, Bistola V, Paraskevaidis I, Ikonomidis I, Gaitani S, Venetsanou K, Filippatos G, and Kremastinos DT

Subjects
Adult, Aged, Analysis of Variance, Cause of Death, Chronic Disease, Cohort Studies, Cytokines blood, Depression complications, Disease-Free Survival, Female, Heart Failure complications, Hospitalization, Humans, Inflammation Mediators blood, Kaplan-Meier Estimate, Male, Middle Aged, Multivariate Analysis, Predictive Value of Tests, Probability, Prognosis, Proportional Hazards Models, Risk Assessment, Severity of Illness Index, Statistics, Nonparametric, Survival Analysis, Depression blood, Depression mortality, Heart Failure blood, Heart Failure mortality, Interleukin-10 blood, Natriuretic Peptide, Brain blood
Abstract

Aims: To assess the prognostic value of a wide spectrum of neurohormonal and inflammatory markers along with functional status and exercise capacity, in hospitalized chronic heart failure (CHF) patients with depressive symptoms., Methods and Results: A total of 300 consecutive hospitalized CHF patients were screened for depressive symptomatology using the Zung self-rated depression scale (SDS). Patients with depressive symptoms (Zung SDS > or = 40) underwent a 6 min walking test, and evaluation of left ventricular ejection fraction, B-type natriuretic peptide (BNP), and plasma inflammatory/anti-inflammatory factors [interleukin (IL)-6, IL-10, tumour necrosis factor-alpha, soluble intercellular adhesion molecule-1, and vascular cell adhesion molecule-1]. Patients were subsequently followed for up to 1 year for major adverse cardiovascular events (MACE, death or hospitalization due to cardiovascular causes). One hundred and fourteen patients (38%) had a Zung SDS > or = 40. One-year event-free survival of these patients was 19% (mean +/- SE, 150 +/- 12 days). In multivariate analysis, only BNP (HR = 1.001, P = 0.002) and IL-10 (HR = 0.864, P = 0.049) were independent predictors of MACE. Using receiver operator characteristics analysis-derived cut-offs, a BNP value of 290 pg/mL predicted MACE with 86% sensitivity and 69% specificity, whereas an IL-10 value of 5 pg/mL predicted MACE with 61% sensitivity and 78% specificity. Event-free survival differed significantly between patients with BNP < 290 pg/mL and IL-10 > 5 pg/mL (261 +/- 44 days) and those with BNP > 290 pg/mL and IL-10 < 5 pg/mL (79 +/- 11 days, P = 0.0001)., Conclusion: Neurohormonal activation and defective anti-inflammatory properties are independent predictors of long-term outcome in hospitalized CHF patients with depressive symptoms.

Published
2009
Full Text
View/download PDF

35. [Efficacy of angiotensin-converting enzyme inhibitors in secondary prevention].

Author

Ceconi C, Mastrorilli F, Squasi PA, Gaitani S, Guardigli G, and Ferrari R

Subjects
Angiotensin-Converting Enzyme Inhibitors administration & dosage, Angiotensin-Converting Enzyme Inhibitors pharmacology, Cardiovascular Diseases mortality, Follow-Up Studies, Forecasting, Heart Failure drug therapy, Humans, Multicenter Studies as Topic, Myocardial Infarction drug therapy, Myocardial Ischemia prevention & control, Prospective Studies, Randomized Controlled Trials as Topic, Renin-Angiotensin System drug effects, Risk, Risk Factors, Time Factors, Ventricular Dysfunction drug therapy, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Cardiovascular Diseases drug therapy, Cardiovascular Diseases prevention & control
Abstract

This paper reports the rationale for the cardiovascular protective effects of angiotensin-converting enzyme (ACE) inhibitors and reviews the overall results of recent randomized clinical trials. ACE-inhibitors prevent degradation of bradykinin, exert anti-ischemic action, inhibit thrombosis and platelet aggregation, are antiatherogenic, improve endothelial function and vessel remodeling, and have anti-inflammatory properties. Previous trials have shown that ACE-inhibitors reduce cardiovascular events in patients with heart failure or ventricular dysfunction. These findings have recently been extended to patients with lower risk profile, no evidence of heart failure and in secondary prevention using lipophilic ACE-inhibitors with high affinity for tissue ACE, i.e. those most likely to have high antiatherosclerotic efficacy. The central role of long-acting lipophilic ACE-inhibitors for cardiovascular protection has been clearly established and they should now be considered as a routine treatment for secondary prevention in the same way as aspirin, beta-blockers and statins.

Published
2005

36. [Markers of coronary damage. From diagnosis to prognosis].

Author

Valgimigli M, Squasi PA, Gaitani S, Arcozzi C, Martano S, and Ferrari R

Subjects
Biomarkers blood, Coronary Disease prevention & control, Diagnosis, Differential, Humans, Interleukin-10 blood, Interleukin-6 blood, Prognosis, Sensitivity and Specificity, Tumor Necrosis Factor-alpha metabolism, Coronary Disease blood, Coronary Disease diagnosis, Cytokines blood, Troponin blood
Abstract

Unlabelled: Cardiovascular disease is a major public health problem. Rapid and accurate diagnosis in the emergency department is essential for timely initiation of treatment, thus any means for improving the speed and accuracy of acute coronary syndrome (ACS) diagnosis can contribute to better clinical and economic outcomes. Measurement of circulating level of troponin has proven to be a sensitive and specific test for cardiac damage detection but they do not discriminate between ischemic and not ischemic etiologies of myocardial injury. Combining troponin with other cardiac biomarkers may offer complimentary information on the underlying pathobiology and prognosis in an individual patient, may increase the analytic sensitivity for myocardial damage and offer insights into the timing and mechanism of myocardial injury. Several prospective epidemiological studies have documented an association between inflammatory markers and cardiovascular disease and their role in primary and secondary prevention and as predictor of mortality., Objective: We sought to report a selected but representative evidence on some new biological markers of cardiac damage, including inflammatory cytokines in patients with cardiovascular disease., Data Sources: We searched in Medline from January 1998 to March 2005 for all studies focusing on the diagnostic and prognostic value of new markers of cardiac damage in patients with ACS and heart failure., Conclusion: The use of necrotic markers to risk stratify patients with chest pain has become an established practice in the clinical setting while the role of other inflammatory biomarkers, despite being still undefined, seems promising under both pathophysiologic and prognostic perspective.

Published
2005

37. First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients.

Author

Piccaluga PP, Martinelli G, Rondoni M, Malagola M, Gaitani S, Visani G, and Baccarani M

Subjects
Acute Disease, Aged, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols toxicity, Gemtuzumab, Hemorrhage chemically induced, Humans, Leukemia, Myeloid complications, Leukemia, Myeloid mortality, Middle Aged, Recurrence, Remission Induction methods, Survival Rate, Treatment Outcome, Aminoglycosides administration & dosage, Antibodies, Monoclonal administration & dosage, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Cytarabine administration & dosage, Leukemia, Myeloid drug therapy
Abstract

Gemtuzumab ozogamicin (GO), an anti-CD33 monoclonal antibody conjugated to calicheamicin, is effective as single agent in the treatment of poor risk acute myeloid leukaemia (AML) patients. We treated with GO in combination with cytarabine as continuous perfusion nine elderly AML patients, either untreated (five cases), or with relapsed/refractory disease (four cases). Five patients achieved a complete remission (CR), four were resistant. One patient died while in CR due to CNS haemorrhage, two relapsed and two are still in CR. The median CR duration was 10 months. The median overall survival was 6 months (1-19 months). The most common adverse event was myelosuppression, as expected. No hepatic veno-occlusive disease was recorded. Notably, in four cases we observed a grade III/IV bleeding, including gasto-intestinal bleeding, epistaxis, CNS haemorrhage, and ocular bleeding. Larger prospective studies are now warranted in order to better define the possible role of this regimen in the treatment of elderly AML patients.

Published
2004
Full Text
View/download PDF

38. Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas.

Author

Piccaluga PP, Martinelli G, Rondoni M, Malagola M, Gaitani S, Isidori A, Bonini A, Gugliotta L, Luppi M, Morselli M, Sparaventi G, Visani G, and Baccarani M

Subjects
Adult, Aged, Aminoglycosides administration & dosage, Aminoglycosides adverse effects, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal, Humanized, Cause of Death, Female, Gemtuzumab, Humans, Immunotherapy, Male, Middle Aged, Recurrence, Treatment Outcome, Aminoglycosides immunology, Aminoglycosides therapeutic use, Antibodies, Monoclonal immunology, Antibodies, Monoclonal therapeutic use, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute immunology, Sarcoma, Myeloid drug therapy, Sarcoma, Myeloid immunology
Abstract

Antibody-targeted chemotherapy is a promising approach in patients with hematological malignancies. In particular, gemtuzumab ozogamicin (GO, formerly CMA-676), an anti-CD33 antibody linked to calicheamicin, has been approved for the treatment of elderly patients with acute myeloid leukemia (AML) in relapse. Nevertheless, no data are until now available concerning the possible efficacy of GO for myeloid sarcomas (MS). We treated with GO 24 AML patients, in 5 cases presenting with myeloid sarcomas of the skin or bones. The overall complete response rate was 21%. The median duration of response was 6 months. Four out of the 5 patients with myeloid sarcoma showed a regression of the masses, in two cases also obtaining a clearance of marrow blasts. The most common adverse events included thrombocytopenia, neutropenia, infections, elevation of bilirubin and hepatic transaminases. Notably, severe bleeding occurred in 5 cases (21%). VOD was documented in 1 case. We conclude that GO is effective as a single agent in AML and myeloid sarcomas. Further data are required to clarify the possible correlation between GO administration and occurrence of bleeding., (Copyright 2004 Taylor and Francis Ltd)

Published
2004
Full Text
View/download PDF

39. Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia.

Author

Piccaluga PP, Luatti S, Ascani S, Bianchini M, Malagola M, Rondoni M, Gaitani S, Testoni N, Pileri SA, Baccarani M, Martinelli G, and Visani G

Subjects
Female, Humans, Immunophenotyping, Karyotyping, Leukemia, Myeloid, Acute immunology, Middle Aged, Chromosomes, Human, Pair 1, Chromosomes, Human, Pair 9, Leukemia, Myeloid, Acute genetics, Translocation, Genetic
Published
2004
Full Text
View/download PDF

40. Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation.

Author

Piccaluga PP, Martinelli G, Malagola M, Rondoni M, Bianchini M, Vigna E, Bosi C, Gaitani S, Visani G, and Baccarani M

Subjects
Adolescent, Adult, Alemtuzumab, Antibodies, Monoclonal pharmacology, Antibodies, Monoclonal, Humanized, Antibodies, Neoplasm pharmacology, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use, Drug Evaluation, Female, Humans, Male, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy, Recurrence, Salvage Therapy methods, Treatment Outcome, Antibodies, Monoclonal therapeutic use, Antibodies, Neoplasm therapeutic use, Graft vs Host Disease drug therapy, Hematopoietic Stem Cell Transplantation adverse effects, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy
Abstract

Despite aggressive approaches, including second transplant, donor lymphocyte infusion and several new agents, the prognosis of acute lymphoid leukemia (ALL) patients relapsing after stem-cell transplantation (SCT) remains poor. Monoclonal-antibodies (moAb) could provide a useful tool in this setting. In particular, anti-CD52 moAb is useful in lymphoid malignancies. We thus treated as compassionate with campath-1H 3 ALL patients relapsed after SCT. In 2 cases we observed a reduction of peripheral blood and/or bone marrow blasts. In 1 case a GVHD grade reduction was observed. Larger trials are required in order to define the role of campath-1H in ALL.

Published
2004
Full Text
View/download PDF

41. Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia.

Author

Piccaluga PP, Malagola M, Rondoni M, Amabile M, Paolini S, Soverini S, Gaitani S, Visani G, Baccarani M, and Martinelli G

Subjects
Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Asparaginase administration & dosage, Benzamides, Doxorubicin administration & dosage, Fusion Proteins, bcr-abl antagonists & inhibitors, Humans, Imatinib Mesylate, Male, Neoplasm Proteins antagonists & inhibitors, Neoplasm Recurrence, Local, Piperazines therapeutic use, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy, Prednisone administration & dosage, Pyrimidines therapeutic use, Remission Induction, Stem Cell Transplantation, Transplantation, Homologous, Vincristine administration & dosage, Drug Resistance, Neoplasm, Piperazines administration & dosage, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Pyrimidines administration & dosage
Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results